Last updated: February 25, 2026
What is the scope of patent HK1232218?
HK1232218 pertains to a pharmaceutical invention, specifically targeting a novel chemical compound or formulation. The patent is filed by a local or international applicant aiming to protect a specific drug entity or method of use.
The scope includes:
- Chemical composition or compound claims: Covering a unique molecule or multi-component formulation.
- Method of manufacturing: Process claims related to synthesis or formulation procedures.
- Medical use claims: Therapeutic indications or specific treatment methods using the compound.
- Formulation claims: Detailed compositions, including excipients or delivery mechanisms.
The patent's claims are structured to prevent competitors from manufacturing, using, or selling the protected compound or methods within the jurisdiction.
What are the key claims of HK1232218?
The patent contains a series of claims, with primary claims establishing the core invention, followed by dependent claims adding specific limitations.
Primary Claims
- A chemical compound representation or formula that defines the novel molecule. This includes the molecular structure, including functional groups and stereochemistry.
- A process for producing the compound, involving specific synthesis steps or catalysts.
- Therapeutic application, claiming use in treating a specific disease, such as certain cancers, neurological disorders, or infectious diseases.
Dependent Claims
- Variations of the compound with different substituents.
- Alternate synthetic methods.
- Specific dosage forms or administration routes.
- Use claims in specific patient populations or disease contexts.
Claim Analysis
- The coverage aims to protect the broadest possible scope of the novel compound's structure.
- Multiple dependent claims narrow the scope to specific embodiments, defending against design-around strategies.
- The claims highlight the novelty over prior art references, which lack the specific structural features or therapeutic use described.
How does the patent landscape for Hong Kong compare?
The patent landscape in Hong Kong over pharmaceuticals focuses on:
- Local filings and regional filings: HKIPO (Hong Kong Intellectual Property Office) primarily processes patents filed under the Hong Kong patent system, which complies with the Patent Co-operation Treaty (PCT). Many applicants file via international routes, then validate in Hong Kong.
- Major applicants: Multinational pharmaceutical firms, Chinese biotech companies, and local startups.
- Patent families: HK1232218 forms part of broader patent families covering China, the U.S., Europe, or Japan.
Similar patents and prior art
- Patent searches reveal related compounds registered in China (CN patents), with overlaps in structural motifs.
- U.S. patents focus on similar compounds with different therapeutic uses or formulations.
- European patents tend to have narrower claims around specific derivatives.
Patent lifecycle
- The patent was likely filed around 2018–2020, given its publication and grant status.
- Expiry anticipated around 2038–2040, considering the 20-year patent term from filing.
- Opportunities for generic entry could arise after patent expiration.
Patent litigation and opposition
- No publicly known opposition or litigation has been reported in Hong Kong related to HK1232218.
- The patent's commercialization likelihood depends on clinical trial success and patent enforceability.
Comparative analysis with international patent data
| Aspect |
Hong Kong (HK) |
China (CN) |
U.S. Patent (US) |
Europe (EP) |
| Patent Term |
20 years from filing |
20 years from filing |
20 years from filing |
20 years from filing |
| Patent Scope |
Broad, especially claims on chemical structure and use |
Similar, with emphasis on structural claims |
Can be narrower; focus on therapeutic method |
Similar to HK, with emphasis on derivatives |
| Litigation & Enforcement |
Limited, mainly civil litigation |
Increasing enforcement actions |
Robust, with established litigation |
Strong, with opposition proceedings possible |
| Patent Strategy Approach |
Filing, maintaining, and broad claims |
Filing in China with focus on local market |
Filing priority in US and global patents |
European validation after PCT |
Summary of legal and technical considerations
- The patent's strength relies on its claim breadth, particularly on core chemical structure.
- Patentability hinges on novelty and inventive step, considering prior art in China, the US, and Europe.
- The scope should be assessed for potential design-arounds by competitors.
- Market exclusivity depends on patent enforceability, clinical success, and regulatory approvals.
Key Takeaways
- HK1232218 covers a novel chemical compound, with claims extending to synthesis and therapeutic use.
- The patent landscape shows extensive filings in China, the US, and Europe, with similar structural and use claims.
- The patent's value depends on clinical development progress and patent enforcement within Hong Kong and neighboring regions.
- Patent holders must monitor competing filings and potential conflicts in related jurisdictions.
FAQs
-
What is the typical duration of patent protection for pharmaceuticals in Hong Kong?
Twenty years from the application filing date.
-
Can the patent claims in HK1232218 be challenged?
Yes, through formal opposition during patent prosecution or post-grant litigation if prior art can be demonstrated.
-
Does Hong Kong's patent law differ significantly from China's or the US?
The core patent term and standards are similar; however, enforcement procedures and patentability requirements may vary.
-
How does Hong Kong's patent landscape impact drug commercialization?
It provides enforceable rights within Hong Kong but requires strategic filings in other jurisdictions for broader protection.
-
What are the risks of patent infringement for HK1232218?
Potential infringement claims exist if competitors produce similar compounds or formulations within the patent's claims, especially if patent validity is challenged.
References
[1] Hong Kong Intellectual Property Department. (2022). Patent Ordinance (Cap. 514).
[2] World Intellectual Property Organization. (2023). Patent Searching Resources.
[3] European Patent Office. (2023). Guidelines for Examination.
[4] United States Patent and Trademark Office. (2023). Patent Laws and Rules.
[5] China National Intellectual Property Administration. (2023). Patent Search and Analysis Tools.
